MARKET

CLVSQ

CLVSQ

Clovis Oncology Inc
OTCPK
0.110
-0.010
-8.33%
Opening 10:07 02/08 EST
OPEN
0.102
PREV CLOSE
0.120
HIGH
0.110
LOW
0.102
VOLUME
7.04K
TURNOVER
774
52 WEEK HIGH
3.320
52 WEEK LOW
0.045
MARKET CAP
15.95M
P/E (TTM)
-0.0604
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/14/2022 21:31
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
Benzinga · 12/14/2022 11:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/13/2022 17:31
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 12/13/2022 17:14
BRIEF-Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
Reuters · 12/13/2022 11:34
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis -- WSJ
Wsj · 12/12/2022 19:05
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
Investor Place · 12/12/2022 15:26
Cancer Focused Clovis Oncology Files For Bankruptcy
Benzinga · 12/12/2022 12:29
More
About CLVSQ
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Webull offers kinds of Clovis Oncology Inc stock information, including OTCPK:CLVSQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVSQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVSQ stock methods without spending real money on the virtual paper trading platform.